Funding news · Oct 12, 2026
Pharmato (药番茄科技) raises seed round led by Enbo Life for medical-AI platform
Pharmato Secures Seed Funding
Pharmato (药番茄科技), a Chinese medical-AI startup founded in 2025 and based in Suzhou, has raised a seed round led by Enbo Life (恩铂生命). The funding was announced on October 12, 2026. The amount of the round was not disclosed.
Company Background
Pharmato was founded in 2025 by two veterans of the pharmaceutical big-data industry. The company is headquartered in Suzhou and operates at the intersection of artificial intelligence and pharmaceutical research.
The Integras Platform
Pharmato's core product is the Integras platform, which combines two main components:
- A multimodal pharma knowledge base — a structured repository of pharmaceutical data designed to support evidence-based analysis.
- High-reliability AI agents — AI systems built for evidence-based analysis and a global drug-pipeline merging tool.
The platform is sold to pharmaceutical companies through a combined model of products, consulting, and data. According to the company, this model has served more than 20 consulting clients and close to 600 enterprise users.
Expansion into Virtual Clinical Trials
Pharmato is extending its technology stack into virtual clinical trials. The company aims to help sponsors and contract research organizations (CROs) identify protocol, enrollment, and cost risks before a trial begins, and to optimize trials while they are running. This expansion moves Pharmato from pharmaceutical data analysis into the clinical development workflow, a potentially larger market with different buyers and regulatory considerations.
Round Details
| Detail | Information |
|---|---|
| Round type | Seed |
| Amount | Not disclosed |
| Currency | CNY |
| Date | October 12, 2026 |
| Lead investor | Enbo Life (恩铂生命) |
| Participating investors | Enbo Life (恩铂生命) |
Enbo Life is the sole investor listed in the available funding data and serves as lead investor. The funding amount was not disclosed.
Strategic Context
Pharmato enters a competitive landscape of AI-enabled drug development tools, but its focus on a multimodal knowledge base combined with AI agents for evidence-based analysis gives it a distinct positioning. The company's traction — more than 20 consulting clients and close to 600 enterprise users — suggests early commercial validation, though specific revenue figures were not disclosed.
The move into virtual clinical trials is notable because trial design and feasibility are areas where data-driven approaches can yield significant cost and time savings. By targeting protocol and enrollment risks before trials start, Pharmato addresses a pain point for sponsors and CROs who face high failure rates and escalating trial costs.
Acquisition Relevance
For acquirers in the pharmaceutical data, clinical research, or AI sectors, Pharmato offers several points of interest:
- Proprietary knowledge base and AI agents — assets that could be integrated into larger pharma data platforms or clinical trial software suites.
- Early commercial traction — a client base of consulting customers and enterprise users provides a foundation for scaling.
- Expansion into clinical trials — a strategic direction that could complement existing CRO or trial technology offerings.
As a seed-stage company founded in 2025, Pharmato is early in its development. The involvement of Enbo Life as lead investor may bring strategic guidance, though the specific terms of the investment were not disclosed.
What to Watch
Observers will be watching how Pharmato converts its consulting and enterprise user base into recurring product revenue, and whether its virtual clinical trial offering gains traction with sponsors and CROs. The company's ability to scale its AI agents and knowledge base across larger pharmaceutical clients will be a key indicator of its growth trajectory.